The field of immunotherapy has been rapidly evolving and is increasingly utilized in the management of lymphomas.¹ Currently, various immunotherapeutic modalities have been pursued including monoclonal antibodies, bispecific T-cell engagers (BiTEs), checkpoint inhibitors and chimeric antigen recepto

Currently, axicabtagene ciloleucel and tisagenlecleucel are two commercially available CAR-T treatment products approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Based on clinical trial results, these cell therapies have demonstrated durable overall response

Primary Sjögren’s Syndrome (pSS) is the second most prevalent systemic autoimmune disease characterized by ocular and oral dryness, musculoskeletal pain, profound fatigue, and an increased risk of lymphoma.¹ Although the symptoms are identifiable, pSS remains incurable due to its